&lsquo;Les liaisons dangereuses&rsquo;: Hepatitis C, Rituximab and B-cell non-Hodgkin&rsquo;s lymphomas

doi:10.4292/wjgpt.v3.i2.21

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3246)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-4) series.

Item

Count

PDF

294

HTML

2632

Tables (1-4)

320

Sum=3246

Apr 6, 2012 (publication date) through Mar 2, 2025

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastrointest Pharmacol Ther. Apr 6, 2012; 3(2): 21-28
Published online Apr 6, 2012. doi: 10.4292/wjgpt.v3.i2.21

Table 4 Mild, moderate and marked elevations of serum liver enzymes

Enzyme	Mild	Moderate	Marked
sAT	> 2-3	2, 3-20	> 20
ALP	< 1.5.2	1.5-5	> 5
γGT	> 2-3	2-3-10	> 10

Numbers are times (X) upper limit of normal value. sAT: Serum aminotransferases; ALP: Alkaline phosphatase; γGT: γ-glutamiltranspeptidase. Adapted from Ahmed et al[57].

Citation: Marignani M, Fonzo MD, Begini P, Gigante E, Deli I, Pellicelli AM, Gallina S, Santis E, Fave GD, Cox MC. ‘Les liaisons dangereuses’: Hepatitis C, Rituximab and B-cell non-Hodgkin’s lymphomas. World J Gastrointest Pharmacol Ther 2012; 3(2): 21-28
URL: https://www.wjgnet.com/2150-5349/full/v3/i2/21.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v3.i2.21